19.24
前日終値:
$19.61
開ける:
$19.98
24時間の取引高:
54,516
Relative Volume:
0.49
時価総額:
$494.95M
収益:
$26.00M
当期純損益:
$-219.71M
株価収益率:
-0.3863
EPS:
-49.8
ネットキャッシュフロー:
$-51.37M
1週間 パフォーマンス:
-2.19%
1か月 パフォーマンス:
-3.07%
6か月 パフォーマンス:
+29.30%
1年 パフォーマンス:
-11.12%
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
名前
Cartesian Therapeutics Inc
セクター
電話
301-348-8698
住所
7495 NEW HORIZON WAY, FREDERICK
RNAC を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
RNAC
Cartesian Therapeutics Inc
|
19.24 | 494.95M | 26.00M | -219.71M | -51.37M | -49.80 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-19 | 開始されました | BTIG Research | Buy |
2024-08-06 | 開始されました | TD Cowen | Buy |
2024-07-02 | ダウングレード | Oppenheimer | Outperform → Perform |
2024-06-04 | 開始されました | Oppenheimer | Outperform |
2024-05-24 | 開始されました | Mizuho | Buy |
2024-04-23 | 繰り返されました | H.C. Wainwright | Buy |
2024-04-23 | 開始されました | Leerink Partners | Outperform |
2023-08-18 | ダウングレード | SVB Securities | Outperform → Market Perform |
2022-06-14 | 繰り返されました | Needham | Buy |
2022-06-06 | 開始されました | SVB Leerink | Outperform |
2021-06-15 | 開始されました | BTIG Research | Buy |
2021-01-26 | アップグレード | Mizuho | Neutral → Buy |
2020-10-01 | ダウングレード | Mizuho | Buy → Neutral |
2020-10-01 | ダウングレード | William Blair | Outperform → Mkt Perform |
2020-06-12 | ダウングレード | Stifel | Buy → Hold |
2020-04-28 | 開始されました | H.C. Wainwright | Buy |
2020-01-29 | 開始されました | Cantor Fitzgerald | Overweight |
2020-01-21 | 開始されました | William Blair | Outperform |
2018-06-27 | 開始されました | Janney | Buy |
2017-03-30 | 繰り返されました | UBS | Buy |
すべてを表示
Cartesian Therapeutics Inc (RNAC) 最新ニュース
Cartesian Therapeutics to Participate in Multiple Upcoming Investor Conferences in February and March 2025 - Nasdaq
Cartesian Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Major mRNA Cell Therapy Player Sets Ambitious 3-Conference Roadshow: Key Dates Inside - StockTitan
Mirae Asset Global Investments Co. Ltd. Has $82,000 Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
What is Leerink Partnrs' Estimate for RNAC FY2024 Earnings? - MarketBeat
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.86 - MarketBeat
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.86 Consensus PT from Analysts - Defense World
Leerink Partnrs Issues Optimistic Estimate for RNAC Earnings - Defense World
RNACCartesian Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
What is Leerink Partnrs’ Forecast for RNAC FY2029 Earnings? - Armenian Reporter
Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
Cartesian Therapeutics Issues Strategic Employee Stock Options Worth $3.3MInside Details - StockTitan
Cartesian Therapeutics (NASDAQ:RNAC) Receives Buy Rating from HC Wainwright - MarketBeat
Cartesian Therapeutics (NASDAQ:RNAC) Given “Buy” Rating at Needham & Company LLC - Defense World
Cartesian Therapeutics Announces FDA Special Protocol - GlobeNewswire
Cartesian Therapeutics Secures FDA SPA Agreement For Phase 3 AURORA Trial - Nasdaq
Cartesian Therapeutics (NASDAQ:RNAC) Earns Buy Rating from Needham & Company LLC - MarketBeat
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis - The Manila Times
Cartesian Therapeutics, Inc. Announces FDA Special Protocol Assessment Agreement for Phase 3 Aurora Trial of Descartes-08 in Myasthenia Gravis - Marketscreener.com
FDA Grants Special Protocol Assessment for Cartesian's Myasthenia Gravis Treatment - StockTitan
Barclays PLC Boosts Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Target Price at $42.86 - Defense World
Cartesian Therapeutics: Need To Wait For More Data For Its Novel mRNA Therapies - Seeking Alpha
Cartesian Therapeutics director Timothy Springer acquires $366k in stock By Investing.com - Investing.com Nigeria
Cartesian Therapeutics director Timothy Springer acquires $366k in stock - Investing.com India
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.86 Consensus PT from Brokerages - MarketBeat
Cartesian Therapeutics’ (RNAC) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Needham & Company LLC Reiterates "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
Cartesian Therapeutics Sets 2025 Strategy for Descartes-08 - TipRanks
Cartesian Therapeutics Highlights Progress and 2025 - GlobeNewswire
Cartesian's Descartes-08 Shows Strong Phase 2b Results in Myasthenia Gravis, Phase 3 Trial Planned - StockTitan
Myasthenia Gravis Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen R&D, Immunovant - The Globe and Mail
Myasthenia Gravis Market Poised for Significant Growth from - openPR
Cartesian Therapeutics chief scientific officer sells $42,782 in stock By Investing.com - Investing.com Australia
Geode Capital Management LLC Raises Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian therapeutics COO Emily English sells $30,149 in stock By Investing.com - Investing.com Nigeria
Cartesian Therapeutics CFO sells shares worth $134,035 By Investing.com - Investing.com South Africa
Carsten Brunn sells $289,764 in Cartesian Therapeutics shares By Investing.com - Investing.com South Africa
Cartesian Therapeutics CTO Metin Kurtoglu sells $81,790 in stock By Investing.com - Investing.com Canada
Cartesian Therapeutics CMO Milos Miljkovic sells $31,541 in stock By Investing.com - Investing.com Nigeria
Cartesian Therapeutics CFO sells shares worth $134,035 - Investing.com India
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Sells $40,412.24 in Stock - MarketBeat
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Metin Kurtoglu Sells 2,458 Shares - MarketBeat
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Insider Milos Miljkovic Sells 948 Shares - MarketBeat
Cartesian Therapeutics chief scientific officer sells $42,782 in stock - Investing.com
Cartesian Therapeutics CTO Metin Kurtoglu sells $81,790 in stock - Investing.com
Carsten Brunn sells $289,764 in Cartesian Therapeutics shares - Investing.com
Cartesian Therapeutics Inc (RNAC) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):